In more detail, while NTRK rearrangements are very rare, being found in <2% of GBM cases and consisting of fusions between NTRK1 and other genes, such as NFASC, BCAN, CHTOP, and ARHGEF2, EGFR in-frame fusions are much more frequent (EGFR-SEPT14 and EGFR-PSPH fusion genes were observed approximately in 4 and 2% of cases) and frequently lead to EGFR overexpression in GBM (8); however, all clinical trials with EGFR inhibitors did not demonstrate longer survival times in GBM patients so far, probably due to the inclusion of poorly homogeneous patient populations. This evidence concerns the gene NTRK1 and glioblastoma.